中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
5期
610-611
,共2页
心肌梗死%心力衰竭%慢性阻塞性肺疾病%比索洛尔
心肌梗死%心力衰竭%慢性阻塞性肺疾病%比索洛爾
심기경사%심력쇠갈%만성조새성폐질병%비색락이
Myocardial infarction%Heart failure%Chronic obstructive pulmonary disease%Bisoprolol
目的 探讨比索洛尔对急性心肌梗死后心力衰竭合并慢性阻塞性肺疾病(COPD)患者心肺功能的影响.方法 选取急性心肌梗死后心力衰竭合并COPD患者86例,分别采用药物溶栓(40例)和经皮冠状动脉介入(PCI)(46例)治疗.所有患者在治疗第2天开始服用富马酸比索洛尔,从2.5 mg/d开始,每3天加1.25 mg,逐渐增至患者最大耐受剂量10 mg/d.共6个月.分别于富马酸比索洛尔治疗前和出院后6个月测定并记录HR、SBP、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左心室短轴缩短指数(FS)、第1秒用力呼气容积占预计值百分比(FEV1％)及第1秒用力呼气容积占用力肺活量百分比(FEV1/FCV).结果 ①药物溶栓者比索洛尔治疗前HR、SBP、LVEDD、LVEF和FS分别为(106±11)次/min、(131±17)mm Hg(1 mmHg =0.133 kPa)、(59.4±2.7) mm、(35.0±2.9)％和(24±5)％,治疗后分别为(75±6)次/min、(111±8)mm Hg、(52.0±3.1)mm、(50.2±4.3)％和(33±5)％；PCI者比索洛尔治疗前分别为(110±13)次/min、(141±7) mm Hg、(61.3±3.3) mm、(34.4±2.5)％和(20±4)％,治疗后分别为(75 ±6)次/min、(120 ±4)mm Hg、(45.0 ±2.2)mm、(56.7±4.6)％和(40±5)％；各项指标治疗前后的差异均有统计学意义(均P＜0.05).②药物溶栓和PCI者应用富马酸比索洛尔治疗前后FEV1％、FEV1/FCV差异均无统计学意义(均P＞0.05).结论 比索洛尔治疗急性心肌梗死后心力衰竭合并COPD是安全有效的.
目的 探討比索洛爾對急性心肌梗死後心力衰竭閤併慢性阻塞性肺疾病(COPD)患者心肺功能的影響.方法 選取急性心肌梗死後心力衰竭閤併COPD患者86例,分彆採用藥物溶栓(40例)和經皮冠狀動脈介入(PCI)(46例)治療.所有患者在治療第2天開始服用富馬痠比索洛爾,從2.5 mg/d開始,每3天加1.25 mg,逐漸增至患者最大耐受劑量10 mg/d.共6箇月.分彆于富馬痠比索洛爾治療前和齣院後6箇月測定併記錄HR、SBP、左心室舒張末期內徑(LVEDD)、左心室射血分數(LVEF)、左心室短軸縮短指數(FS)、第1秒用力呼氣容積佔預計值百分比(FEV1％)及第1秒用力呼氣容積佔用力肺活量百分比(FEV1/FCV).結果 ①藥物溶栓者比索洛爾治療前HR、SBP、LVEDD、LVEF和FS分彆為(106±11)次/min、(131±17)mm Hg(1 mmHg =0.133 kPa)、(59.4±2.7) mm、(35.0±2.9)％和(24±5)％,治療後分彆為(75±6)次/min、(111±8)mm Hg、(52.0±3.1)mm、(50.2±4.3)％和(33±5)％；PCI者比索洛爾治療前分彆為(110±13)次/min、(141±7) mm Hg、(61.3±3.3) mm、(34.4±2.5)％和(20±4)％,治療後分彆為(75 ±6)次/min、(120 ±4)mm Hg、(45.0 ±2.2)mm、(56.7±4.6)％和(40±5)％；各項指標治療前後的差異均有統計學意義(均P＜0.05).②藥物溶栓和PCI者應用富馬痠比索洛爾治療前後FEV1％、FEV1/FCV差異均無統計學意義(均P＞0.05).結論 比索洛爾治療急性心肌梗死後心力衰竭閤併COPD是安全有效的.
목적 탐토비색락이대급성심기경사후심력쇠갈합병만성조새성폐질병(COPD)환자심폐공능적영향.방법 선취급성심기경사후심력쇠갈합병COPD환자86례,분별채용약물용전(40례)화경피관상동맥개입(PCI)(46례)치료.소유환자재치료제2천개시복용부마산비색락이,종2.5 mg/d개시,매3천가1.25 mg,축점증지환자최대내수제량10 mg/d.공6개월.분별우부마산비색락이치료전화출원후6개월측정병기록HR、SBP、좌심실서장말기내경(LVEDD)、좌심실사혈분수(LVEF)、좌심실단축축단지수(FS)、제1초용력호기용적점예계치백분비(FEV1％)급제1초용력호기용적점용력폐활량백분비(FEV1/FCV).결과 ①약물용전자비색락이치료전HR、SBP、LVEDD、LVEF화FS분별위(106±11)차/min、(131±17)mm Hg(1 mmHg =0.133 kPa)、(59.4±2.7) mm、(35.0±2.9)％화(24±5)％,치료후분별위(75±6)차/min、(111±8)mm Hg、(52.0±3.1)mm、(50.2±4.3)％화(33±5)％；PCI자비색락이치료전분별위(110±13)차/min、(141±7) mm Hg、(61.3±3.3) mm、(34.4±2.5)％화(20±4)％,치료후분별위(75 ±6)차/min、(120 ±4)mm Hg、(45.0 ±2.2)mm、(56.7±4.6)％화(40±5)％；각항지표치료전후적차이균유통계학의의(균P＜0.05).②약물용전화PCI자응용부마산비색락이치료전후FEV1％、FEV1/FCV차이균무통계학의의(균P＞0.05).결론 비색락이치료급성심기경사후심력쇠갈합병COPD시안전유효적.
Objective To evaluate the efficacy and safety of bisoprolol in the treatment for patients of heart failure after acute myocardial infarction with chronic obstructive pulmonary disease (COPD).Methods A total of 86 patients of heart failure post acute myocardial infarction with COPD were collected.All the patients received thrombolytic therapy or percutaneous coronary intervention (PCI) respectively according to different myocardial reperfusion treatment strategies.And bisoprolol was administered the second day after admission for a total of 6 months.Heart rate (HR),systolic blood pressure (SBP),left ventricular end diastolic dimension (LVEDD),ejection fraction (LVEF),fractional shortening (FS),as well as percentage of forced expiratory volume in one second to predicted value (FEV1％) and FEV1 to forced vital capacity ratio (FEV1/FCV) were all recorded before admission and 6 months after discharge.Results Before drug thrombolytic treatment,HR,SBP,LVEDD,LVEF and FS of patients receiving thrombolytic therapy values were (106 ± 11) times/min,(131 ± 17)mm Hg,(59.4 ±2.7) mm,(35.0 ± 2.9) ％ and (24 ± 5) ％,bisoprolol after treatment were (75 ± 6) times/min,(111 ± 8) mm Hg,(52.0 ± 3.1) mm,(50.2 ± 4.3) ％ and (33 ± 5) ％ ; Before PCI treatment,HR,SBP,LVEDD,LVEF and FS of patients receiving thrombolytic therapy values were (110 ± 13)times/min,(141 ± 7)mm Hg,(61.3 ±3.3) mm,(34.4 ± 2.5) ％ and (20 ± 4) ％,bisoprolol after treatment were (75 ± 6) times/min,(120 ± 4) mm Hg,(45.0±2.2)mm,(56.7±4.6)％ and (40±5)％ (P＜0.05) ; HR,SBP,LVEDD,LVEF and FS were all improved after treatment (all P ＜ 0.05).There were no difference pertaining to FEV1％ and FEV1/FCV with the use of bisoprolol (all P ＞ 0.05).Conclusion The application of bisoprolol in the treatment of heart failure after acute myocardial infarction with COPD is safe and effective.
